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Denise M. Oliansky,1 Leo I. Gordon,2 Jerry King,3 Ginna Laport,4 John P. Leonard,5
Peter McLaughlin,6 Robert J. Soiffer,7 Koen W. van Besien,8 Michael Werner,9 Roy B. Jones,6
Philip L. McCarthy, Jr.,1 Theresa Hahn1Clinical research examining the role of hematopoietic stem cell transplantation (SCT) in the therapy of fol-
licular non-Hodgkin lymphoma in adults is presented and critically evaluated in this systematic evidence-
based review. Specific criteria were used for searching the published literature and for grading the quality
and strength of the evidence and the strength of the treatment recommendations. Treatment recommenda-
tions reached unanimously by a panel of follicular lymphoma experts are: (1) autologous SCT is recommen-
ded as salvage therapy based on pre-rituximab data, with a significant improvement in overall survival (OS)
and progression-free (PFS) survival; (2) autologous SCT is not recommended as first-line treatment for most
patients because of no significant improvement in OS; (3) autologous SCT is recommended for transformed
follicular lymphoma patients; (4) reduced intensity conditioning before allogeneic SCTappears to be an ac-
ceptable alternative to myeloablative regimens; (5) an HLA-matched unrelated donor appears to be as effec-
tive an HLA-matched related donor for reduced intensity conditioning allogeneic SCT. There are insufficient
data to make a recommendation on the use of autologous SCTafter rituximab-based salvage therapy. Eleven
areas of needed research in the treatment of follicular lymphomawith SCTwere identified and are presented
in the review.
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6/j.bbmt.2010.01.008cell transplantation (SCT) in the therapy of selected
diseases. Seven previous reviews have been published
in Biology of Blood and Marrow Transplantation
(BBMT) on the use of SCT in the therapy of: diffuse
large B cell non-Hodgkin lymphoma (NHL) [1], mul-
tiple myeloma [2], pediatric acute lymphoblastic leu-
kemia (ALL) [3], adult ALL [4], pediatric acute
myelogenous leukemia (AML) [5], adult AML [6],
and myelodysplastic syndromes (MDS) [7]. The goals
of the current review are to assemble and critically
evaluate evidence regarding the role of SCT in the
therapy of follicular lymphoma (FL), make treatment
recommendations based on the available evidence,
and identify areas of needed research.EXPERT PANEL SELECTION
To achieve an appropriate balance, disease-specific
experts who have published studies using SCT and
other therapies are invited to join the independent ex-
pert panel that examines the literature and provides
subsequent treatment recommendations based on the443
Table 1. Grading the Quality of Design and Strength of Evi-
dence
Levels of evidence
1++ High-quality meta-analyses, systematic reviews of randomized
controlled trials (RCTs), or RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews of RCTs, or
RCTs with a low risk of bias
12 Meta-analyses, systematic reviews of RCTs, or
RCTs with a high risk of bias
2++ High-quality systematic reviews of case-controlled or cohort studies.
444 Biol Blood Marrow Transplant 16:443-468, 2010D. M. Oliansky et al.available evidence. For the current evidence-based re-
view, potential panelists were considered based on
their expertise in FL treatment. Potential panelists
are restricted to U.S.-based institutions for 2 reasons:
(1) ease of logistics in convening teleconferences, and
(2) differences in the health care systems and health in-
surance coverage between the United States and other
countries (including Canada, Europe, etc.) that may
result in different expert recommendations based on
considerations of costs and access to care.High-quality case-controlled or cohort studies with a very low
risk of confounding, bias, or chance, and a high probability that the
relationship is causal
2+ Well-conducted case controlled or cohort studies with a low risk of
confounding, bias, or chance, and a moderate probability that the
relationship is causal
22 Case-controlled or cohort studies with a high risk of confounding,
bias, or chance, and a significant risk that the relationship is not
causal
3 Nonanalytic studies (eg, case reports, case series)
4 Expert opinion
Reprinted with permission from Harbour R, Miller J. A new system for
grading recommendations in evidence-based guidelines. Br Med J.
2001;323:334-336.LITERATURE SEARCH METHODOLOGY
PubMed and Medline, the Web sites developed by
the National Center of Biotechnology Information at
the National Library of Medicine of the National In-
stitutes of Health, were searched on June 10, 2008, us-
ing the search terms ‘‘follicular lymphoma’’ and
‘‘transplantation’’ limited to ‘‘human trials,’’ ‘‘English
language,’’ and a publication date of 1990 or later. Up-
dated searches were conducted on January 12, 2009,
and June 9, 2009. In addition to the online database
searches, a manual search of the reference lists of re-
views and included articles was conducted. Papers
published before 1990, that included fewer than 25
FL patients, or were not peer reviewed were excluded.
Also excluded were editorials, letters to the editor,
Phase I (dose escalation or dose finding) studies, re-
views, consensus conference papers, practice guide-
lines, and laboratory studies with no clinical
correlates. Abstracts and presentations at national or
international meetings were not included as evidence
in this review for reasons previously described [3].
To be included in this evidence-based review, at least
65% of a study’s patients had to have FL, unless the re-
sults were stratified by histologic subtype of lym-
phoma.Table 2. Grading the Strength of the Treatment Recom-
mendation
Grades of Recommendation
A At least one meta-analysis, systematic review, or randomized
controlled trial (RCT) rated as 1++, and directly applicable to the
target population; or a systematic review of RCTs or a body of
evidence consisting principally of studies rated as 1+, directly
applicable to the target population, and demonstrating overall
consistency of results
B A body of evidence including studies rated as 2++, directly applicable
to the target population, and demonstrating overall consistency of
results; or extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly applicable
to the target population and demonstrating overall consistency of
results; or extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or extrapolated evidence
from studies rated as 2+
Reprinted with permission from Harbour R, Miller J. A new system for
grading recommendations in evidence-based guidelines. Br Med J.
2001;323:334-336.QUALITATIVE AND QUANTITATIVE
GRADING OF THE EVIDENCE
The hierarchy of evidence, including a grading sys-
tem for the quality and strength of the evidence and
strength of each treatment recommendation, was pub-
lished as an editorial policy statement in BBMT in
2005 [8]. Tables 1 and 2, reprinted from the policy
statement, define criteria used to grade the studies
that were included in this review and criteria to grade
the treatment recommendations, respectively. Study
design, including sample size, patient selection
criteria, duration of follow-up, and treatment plan
also were considered in evaluating the studies. Clinical
studies are described in the review’s text and tables
with sufficient detail to give a concise summary of
study design, sample size, eligibility criteria, treatment
schema, and patient outcomes.All data in the text and tables were abstracted from
the original manuscripts by the first author (D.O.), and
double-checked for accuracy and clarity by two other
authors (T.H. and P.L.M.). Some articles contained
inconsistencies within the data reported; the data
most consistent with the text of the article were in-
cluded in this review. The authors D.O., T.H., and
P.L.M. take responsibility if errors remain.TREATMENT RECOMMENDATIONS
The strength of this review is in the grading of the
strength of the evidence and quality of the study
Table 3. Summary of Treatment Recommendations Made by the Expert Panel for Follicular Non-Hodgkin Lymphoma
Indication for SCT
Treatment
Recommendation
Grade*
Highest Level
of Evidence†
Reference
No.l
Treatment Recommendation
Comments
AUTOLOGOUS SCT VERSUS NONTRANSPLANTATION THERAPY
Autologous SCT versus Nontransplantation therapy
as first-line treatment
A 1++ 9 Although there is consistent improvement in PFS/EFS with autologous SCT, it is not recommended
for most patients because of no significant improvement in overall survival (OS), a higher incidence
of secondary MDS/AML, and a lack of comparative data with rituximab-containing regimens.
Longer follow-up may be needed to identify differences in OS.
Autologous SCT versus nontransplantation therapy
as salvage treatment with rituximab as part of
induction and/or salvage therapy
No recommendation 2+ 16 With only one retrospective study, there are insufficient data to make a recommendation on the use
of autologous SCT versus nontransplantation therapy as salvage treatment for patients who have
had rituximab as part of their induction and/or salvage therapy.
Autologous SCT versus nontransplantation therapy
as salvage treatment without rituximab as part of
induction and/or salvage therapy
A 1- 17 Based on pre-rituximab data, there is a statistically significant improvement in OS and PFS using
autologous SCT as salvage therapy.
Autologous SCT versus nontransplantation therapy
as treatment for transformed FL
D 3 Based on expert opinion and accepted clinical practice, autologous SCT is recommended for
transformed follicular lymphoma patients.
DONOR SELECTION
Autologous SCT versus myeloablative Allogeneic SCT No recommendation 2+ 20-23 There are insufficient data to recommend one option over the other; both appear to have a survival
benefit, but have competing risks. Comparison of these two techniques is biased by different
patient selection criteria.
Autologous SCT versus RIC/NMA Allogeneic SCT No recommendation There are currently no data available to make a recommendation regarding the use of RIC/NMA
allogeneic SCT versus autologous SCT. Comparison of these two techniques is biased by different
patient selection criteria.
AUTOLOGOUS SCT
Autologous SCT as first-line versus salvage treatment
(Timing of SCT)
No recommendation 2- 25 With only one study, there are insufficient data to make a recommendation regarding the efficacy of
autologous SCT as first-line versus salvage therapy.
Rituximab versus no rituximab as part of induction
and/or salvage treatment prior to Autologous SCT
No recommendation 2- 26-28 Because of conflicting data, a recommendation on the use of rituximab as part of induction and/or
salvage therapy prior to autologous SCT cannot be made.
Purged versus unpurged Autologous SCT No recommendation 1- 17 There are insufficient data to make a recommendation regarding purging in autologous SCT.
Comparison of high-dose regimens
for Autologous SCT
No recommendation 2+ 30-32 There are insufficient data to recommend one high dose regimen over another. TBI-containing
regimens are usually avoided because of a concern for a higher risk of secondary MDS/AML.
ALLOGENEIC SCT
Myeloablative versus
reduced-intensity Allogeneic SCT
No recommendation 2++ 33 There are insufficient data to make a recommendation for one conditioning regimen intensity over
another for allogeneic SCT. Based on one study and expert opinion, RIC appears to be an
acceptable alternative approach. Based on expert opinion, an HLA-matched unrelated donor
allogeneic SCT appears to be as effective as an HLA-matched related donor allogeneic SCTusing
RIC.
AML indicates acute myelogenous leukemia; EFS, event-free survival; FL, follicular lymphoma; HLA, human leukocyte antigen; MDS, myelodysplastic syndromes; NMA, nonmyeloablative; OS, overall survival; PFS,
progression-free survival; RIC, reduced-intensity conditioning; SCT, stem cell transplantation; TBI, total body irradiation.
*Definitions: Grade of Recommendation (Table 2): (A) At least 1 meta-analysis, systematic review, or randomized controlled trial (RCT) rated as 1++, and directly applicable to the target population; or a systematic
review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results; (B) A body of evidence including studies
rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+; (C) A body of evidence including studies rated as
2+, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++; (D) Evidence level 3 or 4; or extrapolated evidence from studies
rated as 2+.
†Definitions: Levels of Evidence (Table 1): 1++High quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias; 1+Well-conductedmeta analyses, systematic
reviews of RCTs, or RCTs with a low risk of bias; 12Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias; 2++ High-quality systematic reviews of case-control or cohort studies; or high quality
case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal. 2+Well-conducted case control or cohort studies with a low risk of confounding,
bias, or chance, and a moderate probability that the relationship is causal; 22Case-controlled or cohort studies with a high risk of confounding, bias, or chance, and a significant risk that the relationship is not causal; 3
Nonanalytic studies (eg, case reports, case series); 4 Expert opinion.
lThe references listed represent the highest level of evidence used to make the treatment recommendation and are not inclusive of all evidence described in the review.
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446 Biol Blood Marrow Transplant 16:443-468, 2010D. M. Oliansky et al.designs as described in the text and summary tables in-
cluded in each major section. Table 3 contains the
summary of consensus treatment recommendations
by the FL expert panel based on the summarized evi-
dence.The consensus process involves a teleconference
during which panelists critically discuss the evidence
for each section of the review and develop initial treat-
ment recommendations according to the categories in
Table 2. The information is summarized in Table 3 by
the primary authors and distributed to the panelists for
additional review and clarification. Any changes sug-
gested by an individual panelist are circulated for re-
view and approval by all panelists. This iterative
process concludes when a final version of the Treat-
ment Recommendations table is approved by all panel-
ists. After the final draft of the review is approved by
the disease-specific expert panel, it undergoes peer re-
view, first by the ASBMT Steering Committee for
Evidence-Based Reviews, then by the ASBMT Execu-
tive Committee before submission to the journal. Any
changes requested during the peer-review process
must be reviewed and approved by all disease-specific
expert panelists.FORMATOF THE REVIEW
Evidence is taken from studies that included FL
patients $15 years of age. Studies of ‘‘low-grade lym-
phoma’’ or ‘‘indolent lymphoma’’ patients are included
when FL was the most common subtype included un-
der those broader terms. For each section of the re-
view, a summary paragraph provides an overall
description of the number and types of studies in-
cluded as evidence, as well as a brief synopsis of out-
comes. The design of each study is described in the
text and, unless otherwise noted, an accompanying
summary table in each section presents additional de-
sign and methodology information and patient out-
comes for each study. In each section of this review,
the highest quality studies are presented first; studies
of equal quality are presented in descending order by
study population size. When descriptive information
about a study is not included in the table, such as the
median number of prior chemotherapy regimens or
median time from diagnosis to SCT, it is because the
information was not provided in the article.AUTOLOGOUS SCT VERSUS
NONTRANSPLANTATION THERAPY
This section describes several studies that compare
the impact of first-line or salvage autologous SCT ver-
sus nontransplantation therapy on patient outcomes.
Table 4 presents a summary of the outcomes data
from these studies.First-Line Autologous SCT versus
Nontransplantation Therapy ± Rituximab
There are five randomized studies and one non-
randomized cohort study that examined first-line au-
tologous SCT versus nontransplantation therapy.
The quality of these studies ranged from 111 to 22
(as per Table 1). Two of the randomized studies
included the use of rituximab for stem cell mobiliza-
tion, in vivo purging, or as a component of induction
or high-dose therapy regimens; the remaining four
studies in this section did not use rituximab. Although
the reported follow-up times varied from 4 to 9 years,
in all five randomized studies there was a significant
positive impact on event-free survival (EFS) or
progression-free survival (PFS), but no difference in
overall survival (OS) for patients undergoing first-
line autologous SCT versus those who underwent
standard therapy.Studies of First-Line Autologous SCT versus
Nontransplantation Therapy (with Rituximab)
Ladetto et al. [9] reported the results of a pros-
pective, multicenter study by the Gruppo Italiano
Trapianto di Midollo Osseo/Intergruppo Italiano
Linformi (GITMO/IIL) of 136 adult (18-60 years)
patients with high-risk FL at diagnosis, who were
randomized to receive either six cycles of cyclophos-
phamide 1 doxorubicin 1 vincristine 1 prednisone
(CHOP) followed by six cycles of rituximab (CHOP-
R, n 5 66) or rituximab supplemented high-dose
sequential chemotherapy (R-HDS) followed by an
autologous peripheral blood stem cell transplantation
(PBSCT) purged in vivo with rituximab (n 5 68).
Two CHOP-R patients were not included in the
analysis because of enrollment errors. There were no
significant differences in patient or disease characteris-
tics between the two groups. The CHOP-R and
R-HDS protocols were completed by 71% and 79%
of patients, respectively. Complete remission (CR)
rates were 62% and 85% (P\ .001), and partial remis-
sion (PR) rates were 8% and 5% in the CHOP-R
and R-HDS groups, respectively. Analyses were
based on intention to treat. The R-HDS patients
had a significantly higher 4-year EFS, but not OS,
than the CHOP-R patients. Figure 1 presents the
probability of EFS for patients in the two treatment
arms.
Lenz et al. [10] presented the outcomes of a pro-
spective, multicenter trial by the German Low Grade
Lymphoma Study Group (GLSG) of 440 adult
(27-64 years) patients with indolent lymphoma (75%
follicular, 17% mantle cell, 7% lymphoplasma-
cytic, 2% marginal-zone). After CHOP or CHOP-R
induction therapy, patients were randomized to re-
ceive either interferon-a (IFN-a) maintenance or
high-dose cyclophosphamide (Cy) 1 total body
Table 4. Patient Characteristics and Outcomes from Autologous SCT versus Nontransplantation Therapy Studies
Study Design Patient Outcomes
(Ref #),
Qual. and Strength of Evidence,*
and Patient Population Protocols
Diagnosis or
FL Subtype (at Dx
unless Stated)
Study Groups (n)
(Med Follow-up [Range])
(Interval)
% TRM
(Significance)
(Interval)
% DFS/RFS/PFS/EFS
(Significance)
(Interval)
% OS
(Significance)
(Interval)
% MDS/AML
(Significance)
FIRST-LINE AUTO SCT VERSUS NONTRANSPLANTATION THERAPY (WITH RITUXIMAB)
[9] Auto PBSCT (R-HDS) FL 100% (ITT) Not Stated (4-year EFS) (4-year OS) (4-year)
Ladetto et al. 2008 Induction: APO
1++ FLIPI $3 58% Auto PBSCT (68) 61% 81% 6.6%
2000-2005 Purging: Ritux Stage IV 88%
GITMO/IIL Multictr (30) Non-SCT (66) 28% 80% 1.7%
Enrolled n 5 136 HDT: Mito + Mel
Randomized n 5 134 (P < .001) (P 5.96) (P 5.111)
Non-SCT (CHOP-R) [4.3 y (not stated)]
Med Age (range): 51 y (22-59y) CHOP + Ritux
[10] Induction: FL 75% (As treated) Not Stated (5-year PFS) Not Stated (5-year)
Lenz et al. 2004 CHOP or CHOP-R MC 17%
1+ LPL 6.5% Auto PBSCT (195) 60.2% 3.8%
1996-2002 Auto PBSCT Marginal 1.5% [3.8 y (not stated)] CI 51.1- 69.3%
GLSG Multictr (130) PBSC Mobil: Chemo + GF
Randomized n 5 440 Chemo + IFN-a (236) 31.6% 0%
Evaluable n 5 431 HDT: Cy + TBI Stage IV 77% [3.7 y (not stated)] CI 24.5%-38.8%
(All patients) Chemo + IFN-a (P < .0001) (P 5.0248)
Med Age (range): 50.9 y (27-64y) CHOP-like + IFN-a maint
[11] Auto PBSCT FL 95% (ITT) Not Stated (7-year EFS) (7-year OS) (7-year)
Sebban et al. 2006 Induction: CHOP DLBCL 2.5%
1+ MC 1.5% (FL only) (All patients) (All patients)
1994-2001 PBSC Mobil: Chemo + GF SLL 1%
GELA Multictr (71) Auto PBSCT (192) 76% 1%
Enrolled n 5 402 HDT: Cy + VP-16 + f-TBI FLIPI CI 69%-82%
Randomized n 5 401 Auto PBSCT (FL only, 167) 40%
Confirmed FL n 5 339 Chemo + IFN-a $3 70% CI 33%-48%
CHVP+ INF-a + same maint
(All patients) Chemo + IFN-a Chemo + IFN-a (209) 71% 2%
Med Age (range): 49 y (<61y) $3 68% CI 65%-71%
(FL only, 172) 29%
CI 21%-36%
(7.7 y [not stated])
(P 5 .05) (P 5 .53) (P not stated)
[12] Induction: CHOP or MCP FL 100% (As treated) (Not stated) (5-year PFS) Not Stated Not Stated
Lenz et al. 2004
1+ Auto PBSCT Stage IV 74.2% Auto PBSCT (114) 1.8% 64.7%
1996-2000 PBSC Mobil: Chemo + GF CI 54.6%-74.8%
GLSG Multictr (130)
Enrolled n 5 375 HDT: Cy + TBI Chemo + IFN-a (126) Not stated 33.3%
FL Enrolled n 5 307 CI 24.3%-42.3%
FL Included n 5 240 Chemo + IFN-a (4.2 y [not stated])
CHOP + IFN-a maint (P < .0001)
Med Age (range): 49.1 y (26-59y)
(Continued)
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Table 4. (Continued)
Study Design Patient Outcomes
(Ref #),
Qual. and Strength of Evidence,*
and Patient Population Protocols
Diagnosis or
FL Subtype (at Dx
unless Stated)
Study Groups (n)
(Med Follow-up [Range])
(Interval)
% TRM
(Significance)
(Interval)
% DFS/RFS/PFS/EFS
(Significance)
(Interval)
% OS
(Significance)
(Interval)
% MDS/AML
(Significance)
[13] Auto PBSCT FL 100% (ITT) (Not stated) (9-year EFS) (9-year OS) (9-year)
Gyan et al. 2009 Induction:
1+ VCAP± DHAP (salvage) FLIPI Auto SCT (86) 0% 56% 76% 7%
1994-2001 Auto SCT CI 45%-67% CI 67%-85%
GOELAMS Multictr (25) PBSC Mobil: Chemo $3 70%
Enrolled n 5 172 Chemo+IFN-a Chemo+IFN-a (80) 0% 39% 80% 1%
Randomized n 5 166 Purging varied by center $3 71.5% 28-50% CI 72-89%
(9 y [not stated])
Med Age (range): HDT: Cy + f-TBI (P < .03) (P 5 .55) (P not stated)
Auto SCT 51 y (32-60y)
Chemo+IFN-a 50 y (29-61y) Chemo+IFN-a
Induction: CHVP
Maint: CHVP+ INF-a
[15] Auto SCT FL 100% (Not stated) Not Stated (5-year OS) (69 mos)
Horning et al. 2001 Induction: CVP† 65%
22 + other chemo combo 35% Status at SCT Auto SCT (37) 5% 92% 5%
1988-1994 CR1 22%
Single Ctr BM Mobil: GF PR1 78% Non-SCT (188) Not Stated 88% Not Stated
Auto SCT n 5 37
1962-1988 Historic Control Ex vivo Purging: (P Not stated)
Non-SCT n 5 188 mAbs + Comp (6.5 y [4 -12 y])
Med Age (range): HDT: Cy + VP-16 + f-TBI
Auto SCT 37 y (26-49y)
Non-SCT All #50 y (not stated) Non-SCT
Not specified
Med Dx to SCT (range):
0.8 y (not stated)
SALVAGE AUTO SCT VERSUS NON-TRANSPLANTATION THERAPY (± RITUXIMAB)
[16] Salvage: DHAP or FL 100% Not Stated (5-year EFS) (5-year OS) Not Stated
Sebban et al. 2008 ICE or MINE or Flu-based Auto PBSCT
2+ ± Ritux after Ritux (33) 67% (a) 93% (a)
GELA GELF-86 & GELF-94 HDT: VP-16 + Cy + TBI Auto PBSCT
Multictr or BEAM after No Ritux (65) 46% (b) 63% (b)
Retrospective
Analyzed n 5 246 No Ritux maint. post-HDT Chemo + Ritux (36) 39% (c) 70% (c)
Med age (range not stated): Chemo-only (112) 19% (d) 33% (d)
Auto after Ritux 49 y a vs. b, P 5 .0532 a vs. b, P 5 .0071
Auto after No Ritux 44 y c vs. d, P 5 .0002 c vs. d, P < .0001
Chemo+Ritux 52.5 y (GELF-86 12.8 y a vs. c, P 5 .16 a vs. c, P 5 .13
Chemo-only 52 y GELF-94 7.6 y a + b vs. c + d, a + b vs. c + d,
[ranges not stated]) P < .0001 P < .0001
a + c vs. b + d, a + c vs. b + d,
P < .0001 P < .0001
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[17] Induction: CHOP or other FL 100% (ITT) (Not Stated) (2-year PFS) (4-year OS) Not Stated
Schouten et al. 2003
12 Consolidation: Relapses $2 35% (Chemo) C (24) 0% 26% 46%
1993-1997 Chemo only (C) - CHOP CI 8%-44% CI 25%-67%
EBMT CUP Multictr (36) IPI $3 28%
Enrolled n 5 140 HDT: Cy + f-TBI + (Unpurged Auto BMT)
Randomized n 5 89 Unpurged Auto BMT (U) or U (22) 13.6% 58% 71%
CUP analysis n 5 70 Purged Auto BMT (P) CI 37%-79% CI 52%-91%
Med Age (range): 48 y (29-64) (Purged Auto BMT)
P (24) 8% 55% 77%
CI 34%-75% CI 60%-95%
(5.8 y [not stated])
(P not stated) (P 5 .0037) (P 5 .079)
[18] Salvage varied by physician 100% FL in 1st (Not Stated) Not Stated (5-year OS) (Not stated)
Brice 2000 progression
2++ Auto SCT Auto SCT (83) 6% 58% ± 7.2% 5%
1986-1995 HDT: TBI 71% (HT 24%, 217 pts)
GELA Multictr (40) BEAM 29% Non-SCT (281) 2% 38% ± 3.3% 1%
Retrospective analysis
Eligible n 5 372 Non-SCT (P not stated) (P 5 .0002) (P not stated)
Analyzed n 5 364 Various chemo regimens (3.7 y [not stated])
Med Age (range):
Auto SCT 45 y (17-57y)
Non-SCT 58 y (24-77y)
[19] Auto BMT 100% FL Not Stated Not Stated (5-year OS) (Not Stated)
Rohatiner et al. 2007 HDT: Cy + TBI
22 $CR2 100% Auto BMT (121) Survival 12% (deaths)
1985-1992 Purging: mAbs + Comp estimates were
2 ctrs, Retrospective not provided
n 5 155 Non-SCT Non-SCT (34) See Figure 5 Not Stated
Chlorambucil or CVP
Med Age (range): 43 y (24-61y) Auto SCT versus
(13.5 y [not stated]) Non-SCT
Med Chemo Reg (range): (P 5 .02)
Not stated (2-$3)
Med Dx to SCT (range):
3.3 y (0.3-13.2 y)
aaIPI indicates Age-adjusted International Prognostic Index; APO, doxorubicin/vincristine/prednisone; Auto, autologous; BCNU, carmustine; BEAM, BCNU/etoposide/cytarabine/melphalan; BM(T), bone marrow
(transplantation); CHOP(-R), cyclophosphamide/doxorubicin/vincristine/prednisone(+Rituximab); CHVP, cyclophosphamide/doxorubicin/vepeside/ prednisone; CI, 95% confidence interval; Comp, complement;
Cy, cyclophosphamide; CR, complete remission; CVP, cyclophosphamide/vincristine/prednisone; Dex, dexamethasone; DFS, disease-free survival; DHAP, dexamethasone/cytarabine/cisplatin; Dx, diagnosis; DLBCL,
diffuse large B cell lymphoma; EBMT, European Group for Blood and Marrow Transplantation; EFS, event-free survival; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; f-(TBI),
fractionated (total body irradiation); GF, growth factor; GELA, Groupe d’Etude des Lymphomes de l’Adulte; GITMO/IIL, Gruppo Italiano Trapianto di Midollo Osseo/Intergruppo Italiano Linfomi; GLSG, German
Low Grade Lymphoma Study Group; GOELAMS, Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang; HD, High dose; HDT, High dose therapy; HT, Histologic transformation; ICE, Ifosfamide/carbo-
platin/etoposide; IFN-a , Interferon alfa; IMVP16, Ifosfamide/etoposide/methotrexate; IPI, International Prognostic Index; ITT, intention to treat; LPL, lymphoplasmacytic lymphoma; mAbs, monoclonal antibodies; MC,
mantle cell lymphoma; MCP, Mitoxantrone/chlorambucil/ prednisone; MDS/AML, myelodysplastic syndromes/acute myelogenous leukemia; Mel, melphalan; MINE, mesna/ifosfamide/mitoxantrone/etoposide; Mito,
mitoxantrone; OS, Overall survival; PB(SCT), peripheral blood (stem cell transplantation); PFS, progression-free survival; PR, partial remission; RFS, relapse-free survival; Ref, reference; Ritux, rituximab; SLL, small
lymphocytic lymphoma; SCT, stem cell transplantation; TRM, treatment-related mortality; Tx, treatment; VCAP, vindesine/cyclophosphamide/ doxorubicin/prednisone; VP-16, etoposide.
*Quality and strength of evidence definitions are listed in Table 1.
†CVP and COP both consist of cyclophosphamide/vincristine/prednisone—the acronym CVP was used in this review.
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450 Biol Blood Marrow Transplant 16:443-468, 2010D. M. Oliansky et al.irradiation (TBI), followed by autologous PBSCT.
Three patients in the autologous PBSCT group and
six in the IFN-a group were excluded from the analy-
sis because of lack of diagnostic confirmation. Of the
431 evaluable patients, 236 received IFN-a mainte-
nance and 195 received autologous PBSCT. Although
randomized to the two study groups, the number of
patients in the groups varied because some patients
in the autologous PBSCT group did not have a suffi-
cient stem cell collection to proceed or the patient
refused PBSCT. Analyses were based on treatment re-
ceived. Clinical characteristics of patients in the two
study groups were comparable. The autologous
PBSCT patients had a significantly higher 5-year
PFS than patients in the IFN-a group. OS was not
stated.Studies of First-Line Autologous SCT versus
Nontransplantation Therapy (without
Rituximab)
Sebban et al. [11] reported the results of a prospec-
tive, multicenter study (GELF-94) by the Groupe
d’Etude des Lymphomes de l’Adulte (GELA) of 401
adult (median age, 49 years) patients with untreated
advanced FL (96%) randomized to either CHOP in-
duction therapy then high dose Cy1TBI1 etoposide
followed by autologous PBSCT (n5 192) or induction
therapy consisting of Cy 1 doxorubicin 1 teniposide
1 prednisone (CHVP) followed by CHVP 1 IFN-
amaintenance (n5 209). Patient clinical and biologic
characteristics were similar, as were overall response
rates (78% and 79%, respectively) in the autologous
PBSCT and maintenance groups. Of the 150 eligible
for autologous PBSCT, 131 underwent the procedure.
Analyses were based on intention to treat. FL patients
who underwent autologous SCT had a significantly
higher 7-year EFS, but not OS, than those in the
CHVP 1 IFN-a maintenance group. Figure 2 pres-
ents the probability of EFS for patients in the two
treatment arms.
Lenz et al. [12] reported the outcomes of a sub-
group of 240 adult (26-59 years) patients with FL in
first remission enrolled in a prospective, multicenter
GLSG study of 375 lymphoma patients. After induc-
tion therapy with CHOP or mitoxantrone1 chloram-
bucil 1 prednisone (MCP), patients were randomized
to receive either high-dose therapy with Cy 1 TBI
followed by an autologous PBSCT (n 5 114) or
IFN-a maintenance therapy (n 5 126). In the autolo-
gous PBSCT group, 19.3% and 80.7% of patients
achievedCR and PR, respectively. In the IFN-a group,
15.9% and 84.1% achieved CR and PR, respectively.
Analyses were based on treatment received. The char-
acteristics of patients in the two groups were compara-
ble. Autologous PBSCT patients had a significantly
higher 5-year PFS than IFN-a maintenance patients.OS was not stated. Figure 3 presents the probability
of PFS after autologous PBSCT or IFN-a mainte-
nance.
Gyan et al. [13] presented the long-term results of
a prospective, multicenter study by the Groupe Ouest-
Est des Leucemies et Autres Maladies du Sang (GOE-
LAMS) [14] of 166 adult (18-60 years) patients with
untreated advanced FLwhowere randomized to either
high dose therapy followed by in vivo purged autolo-
gous SCT (n 5 86) or to standard chemotherapy 1
IFN-a maintenance (n 5 80). There were more
women, more patients with B symptoms, and fewer pa-
tients with Grade 3 follicular histology in the mainte-
nance group than in the autologous SCT group.
Ninety percent of autologous SCT, and 77% of stan-
dard chemotherapy patients completed the assigned
treatment. Analyses were based on intention to treat.
Autologous SCT patients had a significantly higher
9-year EFS, but not OS, than IFN-a maintenance
patients.
Horning et al. [15] reported the results of 37 adult
(26-49 years) patients with advanced stage, previously
untreated FL enrolled in a nonrandomized prospective
trial of high-dose therapy consisting of Cy 1 vincris-
tine 1 prednisone (CVP) followed by ex vivo purged
autologous bone marrow transplant (BMT). A refer-
ence sample of 188 patients of similar age, stage, and
histology who received conventional chemotherapy
(no details were reported) was identified for compari-
son of patient outcomes. Five-year OS estimates for
both groups were provided, but not compared.
Salvage Autologous SCT versus
Nontransplantation Therapy ± Rituximab
Four studies examined autologous SCT versus
chemotherapy as salvage therapy for patients with
relapsed/progressed FL. One study investigated autol-
ogous PBSCT after chemotherapy 6 rituximab,
whereas the other three studies did not use rituximab
in their protocols. The quality of these studies ranged
from 12 to 22. The study comparing autologous
PBSCT versus chemotherapy 6 rituximab found that
patients in first relapse who underwent autologous
SCT after salvage including rituximab had improved
5-year OS and EFS after relapse than patients who re-
ceived rituximab-based salvage therapy without an au-
tologous SCT. Of the three studies without rituximab,
one study reported significantly better 2-year PFS,
and two studies reported superior 5-year OS for
patients who underwent salvage autologous SCT
versus chemotherapy.
Study of Salvage Autologous SCT versus
Nontransplantation Therapy (± Rituximab)
Sebban et al. [16] performed a retrospective analy-
sis of a subgroup of 246 adult (18-70 years) patients
Figure 1. The probability of EFS for patients in the two treatment
arms. (This research was originally published in Blood, Ladetto et al.,
2008 [9]. Reprinted with permission. Q 2008 the American Society of
Hematology. All rights reserved.)
Figure 2. The probability of EFS for patients in the two treatment
arms. (This research was originally published in Blood, Sebban et al.,
2006 [11]. Reprinted with permission. Q 2006 the American Society
of Hematology. All rights reserved.)
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treatment in the GELA GELF-94 and GELF-86 pro-
spective, randomized studies, which are described in
this review [11,18]. Patients were compared
according to salvage treatment, as follows:
chemotherapy alone (n 5 112), chemotherapy 1
rituximab (n 5 36), chemotherapy 1 rituximab 1
autologous SCT (n 5 33), or chemotherapy 1 no
rituximab 1 autologous SCT (n 5 65). Patients
treated with rituximab had higher Follicular
Lymphoma International Prognostic Index (FLIPI)
scores and a lower occurrence of B symptoms at
diagnosis, and patients who underwent autologous
SCT were younger and more likely to have relapsed
than progressive disease. OS was highest in patients
who underwent rituximab-based salvage1 autologous
SCT, followed by rituximab-based salvage without
SCT, salvage with no rituximab 1 autologous SCT,
and salvage chemotherapy without rituximab or SCT.Figure 3. PFS after high-dose radiochemotherapy followed by ASCTor
IFN-a maintenance in follicular lymphoma. (This research was originally
published in Blood, Lenz et al., 2004 [12]. Reprinted with permission.
Q 2004 the American Society of Hematology. All rights reserved.)Studies of Salvage Autologous SCT versus
Nontransplantation Therapy (without
Rituximab)
Schouten et al. [17] reported the results of 140
adult (29-64 years) patients with relapsed FL enrolled
in the prospective, multicenter European Group for
Blood and Marrow Transplantation (EBMT) CUP
trial, which compared the effectiveness of standard
therapy (C) versus high-dose therapy followed by un-
purged (U) or ex vivo purged (P) autologous SCT. It
should be noted that recruitment to this trial was dis-
continued because of slow accrual once the sample
size required for the C and P comparison was achieved.The accrual rate was considerably lower than that re-
quired to examine other comparisons adequately. Of
the 140 patients enrolled, 89 patients were random-
ized, 70 among three treatment arms (C, U, and P),
and 19 to only the U and P arms. Reasons for not
randomizing included patient refusal, early progres-
sion, or death after induction therapy. Salvage therapy
was three cycles of CHOP or another regimen. Pa-
tients in the C arm received three additional cycles of
CHOP as consolidation therapy. High-dose therapy
for patients in theU and P arms consisted of Cy1 frac-
tionated TBI (f-TBI), followed by unpurged or purged
autologous SCT, respectively. Of the 70 patients in the
three treatment arms, 88% of the C group, 85% of the
U group, and 67% of the P group received the assigned
treatment. Analyses were based on intention to treat.
Both the purged and unpurged autologous SCT
groups had a significantly higher 2-year PFS, but not
OS, than the chemotherapy-only group. Figure 4
452 Biol Blood Marrow Transplant 16:443-468, 2010D. M. Oliansky et al.presents the probability of PFS for patients in the three
treatment arms.
Brice et al. [18] reported the results of a retro-
spective analysis of 372 adult (17-57 years) patients
with FL who experienced progressive/relapsing dis-
ease after standard chemotherapy in a prospective
GELA study (GELF-86). The median time from
initial treatment to first progression was 24 months.
Of the 372 patients, 281 (75%) received standard
chemotherapy for first progression, and 91 (25%)
patients received salvage therapy consisting of
a TBI-containing regimen (71%) or carmustine 1
etoposide 1 cytarabine 1 melphalan (BEAM) fol-
lowed by autologous (n 5 83) or allogeneic (n 5
8) SCT. Allogeneic SCT patients were excluded
from the analysis. Stem cell source was peripheral
blood (73%) or marrow. Response rates were 88%
and 54% in the autologous SCT versus standard
chemotherapy patients, respectively. Autologous
SCT patients had a significantly higher 5-year OS
than chemotherapy-only patients.
Rohatiner et al. [19] presented the results of a ret-
rospective analysis of 121 adult (24-61 years) patients
with FL who received salvage therapy at the time of
second or subsequent remission consisting of high-
dose Cy 1 TBI followed by ex vivo purged autolo-
gous BMT. Long-term survival outcomes were com-
pared to a historical control group of 34 age-matched,
remission-matched patients who received either
chlorambucil or CVP as initial and salvage therapy.
Actual OS estimates were not provided; however,
Figure 5 compares OS by treatment received and
shows that the Cy 1 TBI 1 autologous BMT pa-
tients had a significantly higher OS than the control
group.Figure 4. The probability of PFS for patients in the three treatment
arms. (Schouten et al., 2003 [17]. Reprinted with permission. Q 2003
American Society of Clinical Oncology. All rights reserved.)AUTOLOGOUS VERSUS ALLOGENEIC SCT
Presented in this section are five studies that com-
pared the outcomes of autologous versus myeloabla-
tive (MA) allogeneic SCT as treatment for refractory
or relapsed FL. The quality of these cohort studies
ranged from 21 to 22. Table 5 presents a summary
of the design, methodology, and outcomes data from
these studies.
In all five studies, allogeneic SCT had a signifi-
cantly higher treatment-related mortality (TRM)
and lower relapse rate compared to autologous
SCT. Few studies reported a significant difference
in survival outcomes between autologous and alloge-
neic SCT. One study reported significantly better 5-
year OS for patients who underwent autologous SCT
compared to allogeneic SCT. Two studies reported
significantly improved disease-free survival (DFS)
for allogeneic compared to unpurged autologous
SCT patients.Studies of Autologous SCT versus Allogeneic
SCT
van Besien et al. [20] reported the results of 904
adult (18-71 years) patients with early (CR1, CR2, or
first relapse) or advanced (.CR2, equal to or greater
than second relapse, or primary induction failure) fol-
licular lymphoma who underwent unpurged (n5 597)
or purged (n5 131) autologous SCT, or human leuko-
cyte antigen (HLA)-identical sibling allogeneic SCT
(n 5 176), and were reported to the International
Bone Marrow Transplant Registry (IBMTR) or the
Autologous Blood and Marrow Transplant Registry
(ABMTR). Time from diagnosis to transplantation
was less than 1 year (19%), 1-2 years (27%), or more
than 2 years (54%). Allogeneic SCT patients hadFigure 5. Comparison of overall survival between patients treated
with Cy1TBI and control group. (Rohatiner et al., 2007 [19]. Reprinted
with permission. Q 2007 American Society of Clinical Oncology. All
rights reserved.)
Figure 6. Probabilities of disease-free survival by type of transplant, ad-
justed for significant covariates. ((This research was originally published
in Blood, van Besien et al., 2003 [20]. Reprinted with permission.Q 2003
the American Society of Hematology. All rights reserved.)
Figure 7. Actuarial probability of DFS for low-grade lymphoma pa-
tients according to type of transplant. (Bierman et al., 2003 [21]. Reprin-
ted with permission.Q 2003 American Society of Clinical Oncology. All
rights reserved.)
Biol Blood Marrow Transplant 16:443-468, 2010 453Role of Cytotoxic Therapy with HSCT in the Treatment of Follicular Lymphomaa significantly higher 5-year DFS than patients who
underwent unpurged autologous SCT. There was no
significant difference in 5-year DFS between alloge-
neic and purged autologous SCT patients, or among
any groups in 5-year OS. Figure 6 presents the proba-
bility of DFS by type of transplantation, adjusted for
significant covariates.
Bierman et al. [21] presented the results of 3376
NHL patients (median age, 42 years), of whom 842
(25%) were low-grade NHL. Outcomes of low-
grade NHL patients from the EBMTR and IBMTR
who underwent syngeneic SCT (n 5 30) were com-
pared to patients from the IBMTR/ABMTR who un-
derwent high-dose therapy followed by unpurged (n5
427) or purged (n 5 160) autologous SCT or T cell-
replete (n 5 189) or T cell-depleted (n 5 36) alloge-
neic SCT. Nonmyeloablative allogeneic SCT patients
were excluded. Allogeneic SCT patients were younger
and more likely to have a history of BM involvement
and high-grade histology than autologous SCT
patients. When compared with syngeneic SCT, un-
purged autologous SCT for low-gradeNHLhad a sig-
nificantly higher risk of relapse (RR, 4.93; P 5 .008),
and DFS was significantly worse for T cell-replete
allogeneic SCT (RR, 3.12; P5 .006) and unpurged au-
tologous SCT (RR, 2.28; P 5 .04) recipients. There
were no significant differences in relapse risk among
syngeneic SCT, purged autologous SCT, and T cell-
replete or T cell-depleted allogeneic SCT recipients.
Low-grade NHL patients who received T cell-
replete allogeneic SCT also had significantly worse
OS than syngeneic SCT patients (RR, 2.87; P 5
.006). There were no significant differences in OS
between autologous and syngeneic SCT. Unpurged
autologous SCT was associated with poorer OS,
when compared to purged autologous SCT (RR,
1.55; P 5 .04). Figure 7 presents the probability of
DFS for low-grade lymphoma patients according to
type of transplantation.
Hosing et al. [22] reported the results of 112 adult
(23-69 years) patients with refractory or relapsedNHL(86% follicular) who underwent either autologous
(n 5 68) or allogeneic (n 5 44) SCT. The 2 groups
were comparable with respect to age at SCT, sex, his-
tologic subtypes, and median number of chemother-
apy regimens before SCT. Donors for allogeneic
SCT were HLA-matched sibling (89%), 1-antigen
HLA-mismatched related (7%), or HLA-matched un-
related (5%). There was no significant difference in
DFS or OS between allogeneic and autologous SCT
patients.
Stein et al. [23] presented the results of 51 adult
(29-63 years) patients with relapsed or refractory
small cleaved cell lymphoma who underwent autol-
ogous (n 5 36) or allogeneic (n 5 15) SCT after
high dose chemotherapy 6 TBI. Allogeneic SCT
patients were significantly younger and had a higher
incidence of BM involvement than autologous SCT
patients. Autologous SCT patients had a significantly
higher 5-year OS, but not PFS, than allogeneic
SCT patients.
Ingram et al. [24] reported the results of 126 adult
(30-74 years) patients with relapsed, advanced stage
FL who underwent BEAM and autologous (n 5 82)
or allogeneic SCT (n 5 44). Donors for allogeneic
SCT were HLA-matched (64%) or $1 antigen
HLA-mismatched (2%) sibling, or HLA-matched
(20%) or HLA-mismatched (14%) unrelated. The al-
logeneic group had a significantly younger median
age than the autologous SCT group. There was no sig-
nificant difference in 3-year DFS or OS between allo-
geneic and autologous SCT patients.AUTOLOGOUS SCT
The autologous SCT section is composed of
nonrandomized comparative and noncomparative
Table 5. Patient Characteristics and Outcomes from Autologous SCT versus Allogeneic SCT Studies
Study Design Patient Outcomes
(Ref #),
Qual. and Strength of Evidence,*
and Patient Population Protocols
Diagnosis or FL
Subtype (at Dx
unless Stated)
Study Groups (n)
(Med Follow-up [Range])
(Interval)
% TRM
(Significance)
(Interval)
% Relapse
(Significance)
(Interval)
% DFS/RFS/ PFS/EFS
(Significance)
(Interval)
% OS
(Significance)
[20] Induction: CHOP ± other FL 100% (5-yr TRM) (5-yr Relapse) (5-year DFS) (5-year OS)
van Besien et al. 2003 or Flu ± other
2+ Stage $III 80% Unpurged Auto (597) 8% CI 6%-11% 58% CI 53%-63% 31% CI 27%-36% 55% CI 50%-60%
1990-1999 Auto SCT (3.4 y [not stated])
IBMTR/ABMTR Multictr (175) Purging: 4-HC Status at SCT
Registered n 5 2459 Early 56% Purged Auto (131) 14% CI 8%-22% 43% CI 35%-54% 39% CI 30%-48% 62% CI 53%-72%
Included n 5 904 HDT: Mostly chemo Advanced 44% (4.1 y [not stated])
Med Age (range): Allo SCT Allo SCT (176) 30% CI 23%-40% 21% CI 15%-28% 45% CI 36%-53% 51% CI 43%-60%
Auto SCT 49 y (18-71 y) y Conditioning: Mostly TBI (3 y [not stated])
Allo SCT 42 y (22-64 y)
Allo vs Auto Allo vs Auto Allo vs (P not
(P < .05) (P < .05) Unpurged significant)
Auto
(P 5 .05)
Allo versus Purged
Auto (P not
significant)
[21] Purging Methods: LG NHL 25% Not Stated
Bierman et al. 2003 4-HC or Mafosfamide 57% IG NHL 55% (LG NHL Only)
2+ Pos Selection tech 12% HG NHL 20%
1985-1998 mAbs 8% Syngeneic (30)
EBMT/IBMTR/ABMTR Other agents 23% Status at SCT (3.7 y [0.3-15.5 y])
Multictr (1286) Refractory 22%
Total n 5 3376 TBI for HDT/Conditioning: CR1 15% Unpurged Auto (427)
LGNHL n 5 842 (Stratified) Syngeneic 28% $CR2 17% (3 y [< 0.8-10.4 y]) See text for See text for See text for
Unpurged Auto 28% Relapse 1 28% RR estimates RR estimates RR estimates
(All patients) Purged Auto 60% Relapse 2 8% Purged Auto (160) of Relapse of DFS for LG of OS for LG
Med Age (range): Replete Allo 72% Unknown 10% (3.8 y [0.3-10.7 y]) for LG NHL NHL NHL
Syngeneic 42 y (4-68 y) Depleted Allo 90%
Auto SCT 48 y (6-71 y) T cell-replete Allo(189)
Allo SCT 35 y (2-62 y) GF Post-SCT 47% (4 y [0.2-14.5 y])
T cell-depleted Allo (36)
(5 y [0.3-13.3 y])
[22] Induction: Flu 35% Auto FL 86% (100 day) (Not stated) (Not stated, (Not stated,
Hosing et al. 2003 57% Allo SLL 14% DFS) OS)
2+ Ritux 2% Auto
1991-2000 9% Allo Ref/Rel 100% Auto SCT (68) 6% 74% CI 59%-88% 17% CI 8%-30% 34% CI 17%-53%
Single Ctr (5.9 y [1.8-9.1 y])
n 5 112 Auto SCT Status at SCT
(All patients) Purging: mAbs 82% Auto SCT Allo SCT (44) 34% 19% CI 9%-38% 45% CI 30%-59% 49% CI 33%-63%
Med Age (range): CR 26% (4.4 y [1.8 -9.4 y])
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Auto SCT 42 y (24-59 y) HDT: Cy + VP-16 + TBI PR 74%
Allo SCT 43 y (23-61 y) (P < .001) (P 5 .003) (P not (P not
Allo SCT Allo SCT significant) significant)
Med Chemo Reg (range): SC Mobil: GF CR 2%
Auto SCT 2 (1-9) PR 98%
Allo SCT 3 (1-6) Conditioning:
Cy + VP-16 + TBI 55%
Med Dx to SCT (range): or BEAM 45%
Auto SCT 3.8 y (0.9 – 15.9 y)
Allo SCT 2.3 y (0.3 – 22.8 y)
(P 5 .002)
[23] Auto SCT SCCL 100% (Not stated) Not Stated (5-year PFS) (5-year OS)
Stein et al. 1999 Purging: VP-16 +
2+ Methylprednisolone 86% Ref/Rel 100% Auto SCT (36) 14% 71% ± 9% 56% ± 11%
1985-1996
Single Ctr HDT: Cy + VP-16 + f-TBI $Stage III 100% Allo SCT (15) 53% 64% ± 15% 15% ± 13%
n 5 51 or CBV
(P not stated) (P 5 .49) (P 5 .012)
Med Age (range): Allo SCT [Not Stated]
Auto SCT 48 y (29-63 y) Conditioning: CBV
Allo SCT 43 y (31-50 y) or Cy + VP-16 + f-TBI
Med Chemo Reg (range):
Auto SCT 2.5 (1-6)
Allo SCT 2 (1-4)
Med Dx to SCT (range):
Auto SCT 3 y (0.5 – 16 y)
Allo SCT 2.5 y (0.6 – 8.9 y)
[24] Auto SCT FL 100% (1-year) (3-year) (3-year DFS) (3-year OS)
Ingram et al. 2008 PBSC Mobil: Chemo + GF
22 Relapsed 100% Auto SCT (82) 2% 43% 56% 67%
1992-2005 HDT: BEAM (7.3 y [0.92-13.9 y])
2 Ctrs $Stage III 100%
n 5 126 Allo SCT Allo SCT (44) 20% 20% 58% 69%
PBSC Mobil: GF (2.9 y [0.55-8.3 y])
Med Age (range): (P 5 .001) (P 5 .01) (P 5 .90) (P 5 .99)
Auto SCT 56 y (30-74 y) Conditioning: BEAM +
Allo SCT 48 y (31-59 y) Alemtuzumab
Med Chemo Reg (range):
Auto SCT 2 (1-6)
Allo SCT 3 (1-8)
Med Dx to SCT (range):
Auto SCT 2.1 y (0.4-10 y)
Allo SCT 2.8 y (0.5-31 y)
4-HC indicates 4-hydroxyperoxycyclophosphamide; ABMTR, Autologous Blood and Marrow Transplant Registry; Allo, Allogeneic; Auto, autologous; BEAM, BCNU/cytarabine/etoposide/ melphalan; BM(T), bone
marrow (transplantation); CBV, cyclophosphamide/BCNU/etoposide; CHOP, cyclophosphamide/doxorubicin/vincristine/prednisone; CI, 95% confidence interval; CR, complete remission; Cy, cyclophosphamide;
DFS, disease-free survival; Dx, diagnosis; EBMT, European Group for Blood and Marrow Transplantation; EFS, event-free survival; FL, follicular lymphoma; Flu, fludarabine; GF, growth factor; HD, high dose;
HDT, High-dose therapy; HG, high grade; IBMTR, International Bone Marrow Transplant Registry; IG, intermediate grade; LG, low grade; mAbs, monoclonal antibodies; NHL, non-Hodgkin lymphoma; OS, overall
survival; PB(SC), peripheral blood (stem cell); PFS, progression-free survival; PR, partial remission; RFS, relapse-free survival; Ref, reference; Ritux, rituximab; SCCL, small cleaved cell lymphoma; SLL, small lymphocytic
lymphoma; SCT, stem cell transplantation; TBI, total body irradiation; TRM, treatment-related mortality; VP-16, etoposide.
*Quality and strength of evidence definitions are listed in Table 1.
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456 Biol Blood Marrow Transplant 16:443-468, 2010D. M. Oliansky et al.studies. Eight nonrandomized comparative studies of
autologous SCT in the treatment of follicular lym-
phoma are summarized in the next section, including
one study that investigated the impact of first-line ver-
sus salvage autologous SCT (timing of transplanta-
tion), three studies that investigated rituximab versus
no rituximab prior to autologous SCT, one study of
purged versus unpurged autologous BMT, and three
studies that compared high-dose therapy regimens
for autologous SCT. All but one of these studies
have a 21 quality rating, the exception has a 22 rating.
Table 6 presents a summary of the design and out-
comes data from the comparative autologous SCT
studies.
In addition, there are 29 noncomparative, single
cohort studies included in this review that examined
the use of autologous SCT as primarily first-line (10
studies) or salvage (13 studies) treatment for FL. Also
included are six noncomparative studies of the effec-
tiveness of autologous SCT with .20% histologically
transformed FL patients. The quality of the noncom-
parative cohort studies ranged from 211 to 21.
These studies represent nonrandomized single- or
multi-institutional experiences with autologous SCT
or retrospective analyses of transplantation registry
data. Collectively, the outcomes data from these stud-
ies contribute to the overall understanding of the effec-
tiveness of autologous SCT in the treatment of FL.
The design, methodology, and outcomes data from
these studies are summarized in Appendix Table 1
(available online only).
Comparative Studies of Autologous SCT
First-line versus Salvage Autologous SCT (Timing of
Transplantation)
One cohort study of the impact of timing of trans-
plantation on FL outcomes examined autologous SCT
as first-line versus salvage therapy. Seyfarth et al. [25]
reported a retrospective analysis of 55 adult (26-60
years) patients with advanced-stage FL who under-
went autologous SCT as first-line (n 5 33) or salvage
(n 5 22) treatment at a single center. Significantly
more first-line patients received TBI therapy and
were in CR or PR at time of mobilization, whereas
more salvage patients had untreated relapsed disease.
Four-year EFS and OS were significantly different in
patients undergoing autologous SCT as first-line ther-
apy versus as salvage therapy.
Rituximab versus no Rituximab Prior to
Autologous SCT
The following three cohort studies examined the
impact of rituximab as part of induction or salvage
therapy prior to SCT on FL or low-grade NHL pa-
tient outcomes. Two studies found no significant dif-
ferences in survival outcomes, whereas one studyreported a significantly improved 5-year EFS and OS
in patients who received pre-SCT rituximab.
Tarella et al. [26] presented a retrospective analysis
of a Gruppo Italiano Terapie Innovative nei Linfomi
(GITIL) study that treated 745 adult (17-65 years)
patients with high-risk FL (n 5 223, 30%) or diffuse
large B cell lymphoma (n 5 522, 70%), comparing
the outcomes of those who received rituximab prior
to first-line or salvage autologous PBSCT versus those
who did not. Patient outcomes were stratified by lym-
phoma histology. Of the FL patients, 116 (52%) re-
ceived rituximab whereas 107 did not, and 94 (42%)
underwent PBSCT as first-line versus 129 as salvage
therapy. Five-year EFS and OS were significantly
higher in FL patients receiving pre-SCT rituximab
versus no rituximab. Figure 8A and B presents esti-
mated EFS for patients who underwent PBSCT as
first-line or salvage therapy, with (R1) or without (R2)
rituximab.
Hoerr et al. [27] presented the results of a retro-
spective analysis of 265 adult (23-73 years) patients
with relapsed low-grade (n 5 111, 42%) or
intermediate-grade (n 5 154) NHL, comparing the
outcomes of those who received rituximab versus those
who did not as part of induction or salvage therapy
prior to autologous SCT. Patients who received ritux-
imab as part of stem-cell mobilization, high-dose
therapy regimen, or post-SCT maintenance were ex-
cluded. Of the low-grade patients, 56 (50%) received
rituximab, and 55 did not. There was no significant dif-
ference in 3-year DFS or OS between pre-SCT ritux-
imab versus no rituximab low-grade NHL patients.
Figure 9 presents the probability of DFS in low-
grade lymphoma patients by pre-SCT rituximab (R
group) versus no rituximab (NR group).
Kang et al. [28] reported the results of a retrospec-
tive analysis of 125 adult (mean age 50 years) patients
with FL who underwent autologous PBSCT. Of
the 125, 19 patients who received rituximab as part
of salvage therapy prior to SCT were excluded. Of
the remaining 106 patients, 35 (33%) received pre-
PBSCT rituximab and 71 did not. There was no signif-
icant difference in median relapse free survival (RFS)
between pre-PBSCT rituximab versus no rituximab
patients.
Purged versus Unpurged Autologous BMT
The randomized CUP trial [18], which examined
the impact of purging in autologous SCT, was previ-
ously described in the Salvage Autologous SCT versus
Nontransplantation Therapy section. In addition, the
following cohort study examined the impact of purged
versus unpurged autologous BMT on low-grade lym-
phoma patient outcomes.
Williams et al. [29] reported the results of an
EBMTR study of 50 adult (17-62 years) low-grade
NHL patients who underwent purged autologous
Table 6. Patient Characteristics and Outcomes from Comparative Autologous SCT Studies
Study Design Patient Outcomes
(Ref #),
Qual. & Strength of Evidence,*
and Patient Population Protocols
Diagnosis or FL
Subtype (at Dx
unless Stated)
Study Groups (n)
(Med Follow-up [range])
(Interval)
% TRM
(Significance)
(Interval)
% DFS/RFS/PFS/EFS
(Significance)
(Interval)
% OS
(Significance)
(Interval)
% MDS/AML
(Significance)
FIRST-LINE VERSUS SALVAGE AUTOLOGOUS SCT (TIMING OF TRANSPLANTATION)
[25] Induction: CHOP, CHOEP, FL 100% (4-year TRM) (4-year EFS) (4-year OS) (4-year)
Seyfarth et al. 2001 CVP, MCP, PmM, or other
22 ± RT $Stage III 100% (Overall)
1992-1999 2%
Single Center SC Mobil: Chemo First-line First-line Auto SCT (33) 76% 92% 0%
n 5 55 CR1 or PR1 85%
HDT: Salvage Auto SCT (22) 38% 73% 0%
Med Age (range): 45 y (26-60 y) Cy + f-TBI 58% Salvage
Bu + Cy 26% Untreated Rel 77% (P < .02) (P 5 .033)
Med Chemo Reg (range): BEAM 16% (4 y (0.8-7.5 y])
1 (1-4)
No exposure to mAbs
Med Dx to SCT (range):
0.9 y (0.4-14 y)
PRE-SCT RITUXIMAB VERSUS NO RITUXIMAB
[26] HDS: FL 30% (Not Stated for (5-year EFS) (5-year OS) Not Stated
Tarella et al. 2008 CHOP ± DHAP ± Ara-C DLBCL 70% FL pts. only)
2+ (FL only)
1986-2005 PBSC Mobil: Chemo ± Ritux (FL only)
GITIL Multictr (10) First-line 42% Ritux Auto PBSCT(116) 66% 82%
n 5 745 HDT: Mito + Mel or BEAM Salvage 58%
FL n 5 223 (Stratified) or other No Ritux Auto PBSCT
(107) 46% 68%
(All patients) Ritux Post-Auto PBSCT
Med Age (range): 47 y (17-65 y) (5 y [not stated]) (P < .001) (P < .011)
[27] Salvage Therapy: LG NHL 42% Not Stated (3-year DFS) (3-year OS) Not Stated
Hoerr et al. 2004 ESHAP, DHAP, MINE, IG NHL 58% (LG NHL only)
2+ or ICE ± Ritux
1996-2002 Relapsed 100% Ritux Auto SCT (56) 53% 73%
Single Ctr SC Mobil: GF [1.5 y (not stated)]
n 5 273
LG NHL n 5 111 (Stratified) HDT: No Ritux Auto SCT (55) 48% 60%
f-TBI 41% (1.8 y [not stated])
(All patients) BEAM 34% (P 5 .46) (P 5 .21)
Med Age (range): BEAC 25%
Ritux 58 y (33-73 y)
No Ritux 50 y (23-69 y) GF Post-Auto SCT
(LG NHL only)
Mean Chemo Cycles (range):
Ritux 14 (not stated)
No Ritux 11 (not stated)
Mean Dx to SCT (range):
Ritux 4.3 y (not stated)
No Ritux 3.3 y (not stated)
(Continued)
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Table 6. (Continued)
Study Design Patient Outcomes
(Ref #),
Qual. & Strength of Evidence,*
and Patient Population Protocols
Diagnosis or FL
Subtype (at Dx
unless Stated)
Study Groups (n)
(Med Follow-up [range])
(Interval)
% TRM
(Significance)
(Interval)
% DFS/RFS/PFS/EFS
(Significance)
(Interval)
% OS
(Significance)
(Interval)
% MDS/AML
(Significance)
[28] Induction: Unspecified chemo FL 100% Not Stated (Median RFS) Not Stated Not Stated
Kang et al. 2007
2+ PBSC Mobil: GF ± chemo IPI at PBSCT Ritux Auto PBSCT (35) 24.6 months
1994-2004 Ritux $3 17% (1.9 y [0.7 -5.2 y])
Single Center HDT: Cy + BU + VP-16 No Ritux $3 33%
n 5 106 No Ritux Auto PBSCT
No maintenance Ritux (71) 49.9 months
Ritux Mean Age: 55 ± 10 y (6.5 y (1.3-10.7 y])
No Ritux Mean Age: 50 ± 9 y (P 5 .47)
(Age ranges not stated)
Med Chemo Reg (range):
Ritux 2 (1-7)
No Ritux 2 (1-6)
Med Dx to SCT (range):
Ritux 2.3 y (0.7-15.3 y)
No Ritux 2.1 y (0.3-17.6 y)
PURGED VERSUS UNPURGED AUTOLOGOUS BMT
[29] Induction: BEAM ± TBI LG NHL 22% (LG NHL) (5-year TRM) (5-year PFS) (5-year OS) Not Stated
Williams et al. 1996 IG NHL 20%
2+ (LG NHL only) Burkitt 18% Purged Auto BMT (50) 10% 48.4% 83.9%
Not stated—1994 Purging: LL 26% (2.5 y [1.7-7.3 y])
EBMTR Multictr (26) Chemical 62% HG NHL 14%
Total n 5 448 mAbs 30% Unpurged Auto BMT
LG NHL n 5 100 (Stratified) CD34+ cell select 8% (LG NHL) (50) 16% 44.2% 47.6%
Status at BMT (2.9 y [0.1-10.9 y])
(LG NHL) HDT: Chemo 57% CR1 26% (P not stated) (P 5 .1757) (P 5 .0184)
Med Age (range): Chemo + TBI 43% CR2/3 26%
Purged 44 y (25-58 y) VGPR 34%
Unpurged 45 y (17-62 y) Refractory 2%
Relapsed 12%
Med Dx to BMT (range):
Purged 1.1 y (0.3-7.8 y)
Unpurged 2.3 y (0.1-22 y)
COMPARISON OF HIGH-DOSE THERAPIES PRIOR TO AUTOLOGOUS SCT
[30] Prior RT: HD-RIT 7% FL 100% (100-day (5-year PFS) (5-year OS)
Gopal et al. 2003 C-HDT 19% TRM)
2+ Ref/Rel 100% Estimated
1990-1998 HD-RIT HD-RIT + Auto (27) 3.7% 48% 67% 8% @ 8 yrs
Single Ctr HDT: 131I-Tositumomab+RT HT:
n 5 125 HD-RIT 15% C-HDT + Auto (98) 11% 29% 53% 9% @ 7 yrs
C-HDT C-HDT 8%
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Med Age (range): HDT: Cy+VP-16+TBI 59% (P 5 .10) (P 5 .06) (P 5 .02) (P not stated)
HD-RIT 46 y (24-59 y) Cy+TBI 11% Status at SCT (Not Stated)
C-HDT 49 y (30-59 y) Bu+Mel+TT 21% HD-RIT
Other combo 9% CR/PR 59%
Med Chemo Reg (range): Ref/Rel 41%
HD-RIT 2 (1-6)
C-HDT 2 (1-11) C-HDT
CR/PR 68%
Ref/Rel 32%
[31] Prior RT: LG NHL 35% (Not stated) (5-year EFS) Not Stated for (4-year)
Gutierrez-Delgado et al. 2001 TBI+Cy+VP-16 0% Aggress NHL 63% (LG NHL) LG NHL Only
2+ Bu+Mel+TT 45% SLL 2%
1990-1998 TBI+Cy+VP-16+Auto
Single Ctr BM Purging: Status at SCT (76) 13% 37% 3%
Total n 5 351 Anti-B mAbs 19% TBI+Cy+VP-16 (5 y [1-9 y])
LG NHL n 5 106 (Stratified) Anti-T mAbs 3% CR1 4%
$CR2 15% Bu+Mel+TT+Auto (30) 17% 36% 0%
(All patients) PBSC Mobil: GF alone 26% Ref/Rel 81% (3.5 y [1-6 y])
Med Age (range): Chemo + GF 58% (P 5 .80) (P not (P not stated)
TBI+Cy+VP-16 47 y (18-65 y) Bu+Mel+TT significant)
Bu+Mel+TT 48 y (19-67 y) RT Post-Auto SCT: CR1 5%
TBI+Cy+VP-16 5% $ CR2 19%
Med Chemo Reg (range): Bu+Mel+TT 8% Ref/Rel 76%
2 (1-7)
[32] Prior RT: Bu + Cy 41% FL 82% (3.6-yr TRM) (3.6-yr EFS) (3.6-yr OS) Not Stated
Weaver et al. 1998 BEAC 30% SLL 18%
2+ Bu + Cy +Auto PBSCT
1991-1995 PBSC Mobil: Chemo + GF Status at SCT (22) 9% 36% 58%
Multictr (19) Bu+Cy
n 5 49 HDT: Bu + Cy 45% Refractory 50% BEAC + Auto PBSCT
(All patients) BEAC 55% Relapsed 50% (27) 7% 28% 55%
Med Age (range):
Bu+Cy 46 y (25-62 y) GF Post-PBSCT 80% BEAC (3.6 yrs [not stated]) (P not stated) (P 5 .82) (P 5 .72)
BEAC 53 y (22-64 y) Refractory 33%
Relapsed 67%
Med Chemo Reg (range):
Not stated (1- $3)
Auto indicates autologous; BCNU, carmustine; BEAC, carmustine/etoposide/cytarabine/cyclophosphamide; BEAM, carmustine/etoposide/cytarabine/melphalan; BEM, carmustine/etoposide/melphalan; BM(T), bone
marrow (transplantation), Bu, Busulfan; CBV, cyclophosphamide/carmustine/etoposide; C-HDT, Conventional high dose therapy + Auto SCTChemo, Chemotherapy; CHOEP, Cyclophosphamide/doxorubicin/etopo-
side/prednisone; CHOP(-R), cyclophosphamide/doxorubicin/vincristine/prednisone(+Rituximab); CI, 95% Confidence interval; CR, Complete remission; CVP, cyclophosphamide/ vincristine/prednisone; Cy, cyclo-
phosphamide; DFS, disease-free survival; DHAP, dexamethasone/cytarabine/cisplatin; DLCL, Diffuse large cell lymphoma; Dx, diagnosis; EBMTR, European Group for Blood and Marrow Transplantation Registry; EFS,
event-free survival; ESHAP, etoposide/solumedrol/cytarabine/platinum; FL, Follicular lymphoma; Flu, fludarabine; f-TBI, fractionated total-body irradiation; GF, growth factor; GITIL, Gruppo Italiano Terapie Innno-
vative nei Linfomi; HD, High dose; HD-RIT, high-dose radioimmunotherapy + Auto SCT; HDT, high-dose therapy; HG, high grade; HT, histologic transformation; ICE, ifosfamide/carboplatin/etoposide; IG, intermediate
grade; IPI, International Prognostic Index; LDH, lactate dehydrogenase; LG, low grade; LL, lymphoblastic leukemia; mAbs, monoclonal antibodies; MCP, mitoxantrone/chlorambucil/prednisone; Mel, melphalan; MINE,
mesna/ifosfamide/mitoxantrone/etoposide; Mito, mitoxantrone; MTX, methotrexate; NHL, non-Hodgkin lymphoma; NT, not transformed; OS, overall survival; PBSC(T), peripheral blood stem cell (transplantation);
PFS, progression-free survival; PmM, prednimustine/mitoxantrone; PR, partial remission; Ref, reference; RFS, relapse-free survival; Ritux, rituximab; RT, radiation therapy; SCT, stem cell transplantation; SLL, small
lymphocytic lymphoma; T, transformed; TBI, total-body irradiation; TRM, treatment-related mortality; TT, thiotepa; Tx, treatment; VGPR, very good partial response; VP-16, etoposide; WF, Working Formulation.
*Quality and strength of evidence definitions are listed in Table 1.
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Figure 8. Estimated EFS for patients who underwent PBSCTwith (R1)
or without (R–) rituximab according to disease status. (A) Patients re-
ceiving PBSCT first-line therapy. (B) Patients receiving PBSCTas salvage
therapy for refractory disease or early relapse. (Tarella et al., 2008 [26].
Reprinted with permission.Q 2008 American Society of Clinical Oncol-
ogy. All rights reserved.)
Figure 9. DFS in low-grade lymphoma patients by pre-SCT rituximab
(R group) versus no rituximab (NR group). (Hoerr et al., 2004 [27]. Re-
printed with permission.Q 2004 American Society of Clinical Oncology.
All rights reserved.)
460 Biol Blood Marrow Transplant 16:443-468, 2010D. M. Oliansky et al.BMT, compared to 50 matched low-grade NHL pa-
tients who underwent unpurged autologous BMT.
Significantly more unpurged autologous BMT pa-
tients received a high dose therapy regimen containing
TBI (28 versus 15, P 5 .0164). Although there was no
significant difference in 5-year PFS between the
groups, 5-year OS was significantly improved after
purged autologous BMT.Comparison of High-Dose Therapies Prior to
Autologous SCT
Three studies compared two different high-dose
therapy regimens prior to autologous SCT. One study
reported a significantly better 5-year OS for patients
receiving radioimmunotherapy versus standard high-
dose therapy prior to autologous SCT. The other
two studies reported no significant differences in sur-
vival outcomes comparing TBI 1 Cy 1 etoposide(VP-16) versus busulfan 1 melphalan 1 thiotepa
(Bu/Mel/T), or comparing Bu 1 Cy versus BCNU
(carmustine) 1 VP-16 1 cytarabine 1 Cy (BEAC)
prior to autologous SCT.
Gopal et al. [30] reported the results of a single
center study of 125 adult (24-59 years) patients with re-
lapsed FL, comparing the outcomes of 27 patients
treated with high-dose anti-CD20 radioimmunother-
apy (131I-tositumomab) plus autologous SCT versus
98 nonrandomized control patients treated with con-
ventional high-dose chemotherapy regimens followed
by autologous SCT. Significantly more patients in the
radioimmunotherapy 1 autologous SCT group had
elevated lactate dehydrogenase (LDH) (41% versus
20%, P 5 .03) and an International Prognostic Index
(IPI) score $2 (41% versus 16%, P 5 .02) compared
to patients undergoing conventional high-dose ther-
apy and autologous SCT. Patients receiving radioim-
munotherapy prior to autologous SCT had
a significantly higher 5-year OS, but not PFS, than pa-
tients receiving standard chemotherapy prior to autol-
ogous SCT.
Gutierrez-Delgado et al. [31] presented the results
of a single center study of 351 adult (18-67 years) pa-
tients withNHL.Of these, 106 (30%) patients with in-
dolent NHL underwent autologous SCT following
high-dose therapy with either TBI 1 Cy 1 VP-16 (n
5 76) or BuMelT, n 5 30). Forty-five percent of the
Bu/Mel/T patients had undergone prior radiation
therapy and were not eligible to receive TBI 1 Cy 1
VP-16. Significantly more patients in the TBI 1 Cy
1 VP-16 group had BM involvement prior to HSCT
(15% versus 5%, P 5 .004), whereas the Bu/Mel/T
group had more patients .60 years and with aggres-
sive histology (P\ .005). There was no significant dif-
ference in 5-year EFS between patients in the two
conditioning regimens.
Weaver et al. [32] reported the results of a multi-
center study of 49 adult (25-62 years) patients with re-
fractory or relapsed low-grade NHL (follicular
lymphoma, 82%) who underwent high-dose therapy
with either Bu 1 Cy (n 5 22) or BEAC (n 5 27) prior
to an unpurged autologous PBSCT. BEAC patients
Biol Blood Marrow Transplant 16:443-468, 2010 461Role of Cytotoxic Therapy with HSCT in the Treatment of Follicular Lymphomawere significantly older (P 5 .031) and included more
females (P5 .025) than the Bu1Cy group. There was
no significant difference in 3.6-year EFS or OS be-
tween patients in the two conditioning regimens.ALLOGENEIC SCT
This section includes one comparative study de-
scribed in the following section of MA versus reduced
intensity conditioning (RIC) allogeneic SCT. The
quality rating for this study was 211. Table 7 provides
a summary of the design, methodology, and outcomes
data from this study, which found no significant differ-
ence in outcomes by conditioning regimen intensity.
Also included in this section are 12 noncompara-
tive cohort studies of allogeneic SCT using either
MA (5 studies) or RIC (7 studies) regimens. The qual-
ity ratings for these studies ranged from 211 to 21.
The design, methodology, and outcomes data from
these studies are summarized in Appendix Table 2 (on-
line only). Overall, the outcomes data from these stud-
ies contribute to the overall understanding of the
effectiveness of allogeneic SCT in the treatment of fol-
licular lymphoma.
Myeloablative versus Reduced Intensity
Allogeneic SCT
Hari et al. [33] presented the results of a multicen-
ter, retrospective study of 208 adult (27-70 years) pa-
tients with FL reported to the Center for
International Blood and Marrow Transplant Research
(CIBMTR), comparing the outcomes of those who un-
derwent MA (n 5 120) conditioning versus RIC (n 5
88) prior to an HLA-identical sibling allogeneic
SCT. Recipients of unrelated donor allogeneic SCT
and/or ex vivo T cell-depleted grafts were excluded.
RIC was defined by the CIBMTR as TBI\5 Gy as
a single fraction, Bu doses \9 mg/kg, Mel doses
#150mg/m2, and fludarabine-based regimens without
MA doses of TBI, Bu, or Mel. Use of RIC increased
from\10% of transplantations in 1997 to .80% of
transplantations in 2002. The RIC cohort was signifi-
cantly older, more likely to be in $CR2 at SCT, had
a longer interval from diagnosis to SCT, and were
more likely to have received rituximab prior to SCT,
whereas the MA cohort had a higher proportion of pa-
tients with primary induction failure and a higher inci-
dence of BM involvement. There was no significant
difference in 3-year PFS or OS between patients in
the MA and RIC groups.PROGNOSTIC FACTORS
Table 8 summarizes patient- and disease-related
prognostic factors found to have a positive or no im-
pact on survival outcomes, as determined by multivar-iate analyses. Studies were not included in this table if
they did not conduct a multivariate analysis. This table
is provided for the reader’s information and was not
used to make treatment recommendations.FUTURE DIRECTIONS
Areas of Needed Research
After reviewing the evidence, the expert panel
identified the following important areas of needed re-
search in FL:
1) Rituximab-based therapy followed by autologous
SCT versus rituximab-based therapy without
SCT.
2) Post-autologous SCT rituximab maintenance
therapy versus no post-autologous SCT mainte-
nance rituximab.
3) Ex vivo purged autologous SCT.
4) T cell-depleted allogeneic SCT.
5) Comparison of matched-related versus matched-
unrelated or other alternative donor for allogeneic
SCT.
6) The efficacy and toxicity of reduced intensity reg-
imens before autologous and allogeneic SCT.
7) RIC allogeneic SCT as salvage therapy after failed
autologous SCT.
8) Radioimmunotherapy as part of the preparatory
regimen for autologous SCT or RIC allogeneic
SCT.
9) The impact of radioimmunotherapy and newer
agents (ie, bendamustine, rituximab, alemtuzu-
mab, fludarabine, etc.) on stem cell quality.
10) Identification of surrogate molecular markers pre-
SCT that are predictive of long-term survival in
FL patients.
11) The association of FLIPI score at diagnosis and at
SCT with prognosis in FL patients.Ongoing Studies
Several studies are summarized below that address
areas of needed research or other issues that may ulti-
mately affect the treatment recommendations made in
Table 3. These studies are currently accruing patients,
are ongoing, or have been published in abstract form.
None of the data described below was used as evidence
for the review or used for making treatment recom-
mendations. This section is provided for the reader’s
information only.
Rituximab Prior to Autologous SCT
Rituximab as first-line therapy
At a median follow-up of 58 months, Buske et al.
[34] reported on a GLSG trial of 552 patients with
newly diagnosed advanced stage follicular lymphoma
Table 7. Patient Characteristics and Outcomes from Myeloablative versus RIC Allogeneic SCT Study
Study Design Patient Outcomes
(Ref #),
Qual. & Strength of Evidence,*
and Patient Population Protocols
Diagnosis or
Stage (at Dx
unless stated) Study Groups (n)
(Interval)
% TRM
(Significance)
(Interval)
% Relapse
(Significance)
(Interval)
% DFS/RFS/PFS/EFS
(Significance)
(Interval)
% OS
(Significance)
[33] Pre-SCT Ritux: FL 100% (HLA-identical
Sib Donors)
(3-year TRM) (3-yr Relapse) (3-year PFS) (3-year OS)
Hari et al. 2008 MAT 26%
2++ RIC 45% Mostly Ref/Rel MATAllo SCT (120) 25% 8% 67% 71%
1997-2002 [4.2 y (0.3-8 y)] CI 17-33% CI 4-14% CI 58-75% CI 63-79%
CIBMTR Prior Auto SCT: Status at SCT
Multicenter (> 500) MAT 6% MAT RIC Allo SCT (88) 28% 17% 55% 62%
n5208 RIC 10% Refractory 36% [2.9 y (0.3 -6.8 y)] CI 19-38% CI 10-26% CI 44-65% CI 51-72%
CR1 8%
Med Age (range): Conditioning: $ CR2 11% (P 5 .60) (P 5 .06) (P 5 .07) (P 5.15)
MAT 44 y (27-70 y) MAT Cy + TBI 67% $1 Relapse 45%
RIC 51 y (27-70 y) Bu + Cy 25%
TBI only 8% RIC
Med Chemo Reg (range): Refractory 26%
Not stated (1- $ 4) RIC Flu + Cy 42% CR1 3%
Flu + Bu 25% $ CR2 22%
Med Dx to SCT (range): Flu + Mel ± ATG 18% $1 Relapse 49%
MAT 2.1 y (0.3-16.5 y) Flu + TBI 10%
RIC 3 y (0.5-16.3 y) Other 5%
Allo indicates Allogeneic; ATG, Antithymocyte globulin; Bu, Busulfan; Chemo, Chemotherapy; CI, 95% Confidence interval; CIBMTR, Center for Inter-
national Blood and Marrow Transplant Research; CR, Complete remission; Cy, Cyclophosphamide; DFS, Disease-free survival; Dx, Diagnosis; EFS,
Event-free survival; FL, Follicular lymphoma; Flu, Fludarabine; HLA, Human leukocyte antigen; MAT, Myeloablative therapy; Mel, Melphalan; OS, Overall
survival; PFS, Progression-free survival; RFS, Relapse-free survival; Ref, Reference; RIC, Reduced intensity conditioning; SCT, Stem cell transplantation;
Sib, sibling; TBI, Total body irradiation; TRM, Treatment-related mortality
*Quality and strength of evidence definitions are listed in Table 1.
462 Biol Blood Marrow Transplant 16:443-468, 2010D. M. Oliansky et al.randomized between R-CHOP versus CHOP, fol-
lowed by a second randomization in responding
patients\60 years to IFN-a maintenance versus MA
chemotherapy plus autologous SCT. All patients
$60 years received IFN-a maintenance. Five-year
OS was significantly improved for R-CHOP versus
CHOP (90% versus 84%, P 5 .049), but only in pa-
tients who did not undergo autologous SCT (OS;
IFN-a, 78% versus auto SCT, 66%, P 5 .43).
Rituximab as salvage therapy
Weigert et al. [35] reported the outcome of autol-
ogous SCT after the addition or not of rituximab to
salvage regimens in 167 adult (19-64 years) patients
with relapsed or refractory follicular lymphoma in
a retrospective analysis of 2 randomized, multicenter
GLSG trials (MCP versus CHOP and CHOP versus
R-CHOP, both followed by randomization to IFN-
a maintenance versus autologous SCT). The median
PFS and OS for patients treated with or without ritux-
imab were 3.4 versus 2.8 years and 8.3 versus 7.2 years,
respectively. Sixty-six patients (40% of eligible) re-
ceived autologous SCT, 31 of whom were treated
with prior rituximab. The median PFS for patients re-
ceiving autologous SCT or not was 5.5 versus 2.3 years
(P 5 .038), respectively. Subgroup analysis found that
the addition of rituximab to salvage therapy primarily
benefited patients who did not undergo autologous
SCT.Rituximab as in vivo purging pre-SCTand
maintenance therapy post-SCT
The EBMT Solid Tumors Working Party has
sponsored a Phase III, randomized, multicenter trial
(NCT00005589) comparing combination chemother-
apy and autologous PBSCT with or without rituximab
as in vivo purging pre-SCT and maintenance therapy
post-PBSCT in adult ($18 years) patients with re-
lapsed FL. A total accrual of 460 patients (115 to
each of 4 treatment arms) is projected. Time to disease
progression is the primary outcome measure, with re-
sponse rate, survival, and molecular remission rates as
secondary outcome measures of interest.
Rupolo et al. [36] reported the outcomes of 34
adult (30-66 years) patients enrolled between 2002
and 2007 in a nonrandomized, single-center study. Pa-
tients who responded to salvage therapy (R-DHAOX)
underwent high-dose chemotherapy with BEAM-R,
followed by autologous SCT, followed by mainte-
nance therapy with rituximab for two years. Sixty-
eight percent of patients had FL, 29% had mantle
cell, and one patient had transformed FL. At 32
months follow-up from salvage therapy, 5-year pro-
jected PFS was 78% for FL patients.
Cheung et al. [37] reported the outcomes of 29
adult (30-65 years) patients with relapsed high-risk
FL enrolled in a single center Phase II study investigat-
ing the impact of achieving a molecular remission after
in vivo purging with rituximab and post-SCT
Table 8. Patient and Disease-Based Prognostic Factors Found to Have a Positive Impact on Survival* Outcomes as Determined by
Multivariate Analysis in the Referenced Studies
Favorable Prognostic Factor†
Studies Reporting Significant Positive Impact
of Prognostic Factor on Survival
Studies Reporting No Impact of the
Prognostic Factor on Survival
PATIENT-RELATED FACTORS
Younger age 20, 27, 45, 55, 59, 61, 63, 69, 70, 73, 74, 83, 84, 85 44, 46, 47, 56, 64, 68, 71, 72
Female gender 46 25, 44, 47, 55, 64
DISEASE-RELATED FACTORS
Early stage (versus advanced or transformed) 20, 31, 60, 61, 62, 68 24, 44, 45, 47, 72
Less aggressive histology (FL versus DLBCL) 26, 31, 48, 82, 83, 84 55, 64, 65, 71
Better performance status (ECOG #2
or Karnofsky $90)
9, 13, 20, 33, 74, 82 12
No prior bone marrow involvement 23, 47, 58, 64 46, 56, 73
Lower serum LDH at diagnosis 20 12, 44, 46, 72
Lower serum LDH at SCT 30, 45, 61 55
Fewer extranodal sites 12, 13, 45, 46 44, 47, 70, 72
Lower FLIPI or IPI score (#2) 26, 30, 60, 63 13, 44, 47, 50
No B symptoms 9, 76
No bulky disease at diagnosis 47 55, 70, 72
No bulky disease at SCT 68, 73
TRANSPLANTATION-RELATED FACTORS
Chemosensitivity (in CR at SCT) 9, 20, 23, 26, 33, 45, 55, 59, 61, 68, 69, 73, 74, 78, 80, 83 24, 46, 49, 63, 64, 65, 70, 71, 72, 82
Fewer courses or lines of chemotherapy 24, 27, 55, 57, 58, 61 23, 45, 46, 49, 52, 56, 59, 62, 73
Molecular remission after SCT 9, 44, 48, 51, 54, 57, 63 55, 68
Use of autologous SCT (versus other therapy) 9, 12, 13, 20, 23
Non-TBI or f-TBI-based therapy 29, 57, 61, 74 55, 68
Shorter interval from diagnosis to SCT 20, 48, 82 24, 45, 59, 63, 68, 72
Use of rituximab pre-SCTor salvage 26, 72 28, 45, 64
Purged autologous BMT (versus unpurged) 21, 29 25, 63
No development of acute GVHD grades 3-4 76, 78
Transplantation after mid-1990s 20 73
Auto SCT as first-line therapy (versus as
salvage therapy)
25 52
Methotrexate-containing GVHD prophylaxis 82
Large transplantation center 29
BMT indicates bone marrow transplantation; CR, complete remission; DLBCL, diffuse large B cell lymphoma; ECOG, Eastern Cooperative Oncology
Group; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; f-TBI, fractionated total-body irradiation; GVHD, graft-
versus-host disease; IPI, International Prognostic Index; LDH, lactate dehydrogenase; SCT, stem cell transplantation; TBI, total-body irradiation.
Quality and strength of evidence definitions are listed in Table 1.
*Survival 5 any 1 or more of the following: OS, DFS, EFS, FFS, LFS, PFS, RFS.
†Factors were not included if the study did not conduct a multivariate analysis.
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IFN-a. Of the 17 grafts purged with rituximab, 8 still
had molecular disease pre-SCT. Of 16 assessable pa-
tients post-SCT, 11 achieved molecular remission
prior to maintenance immunotherapy, and all 16
achieved molecular remission during maintenance.
Median PFS for all patients is 50 months; median
OS has not been reached.Chemotherapy 1 IFN-a versus autologous
PBSCT 1 IFN-amaintenance
The European Organization for Research and
Treatment of Cancer (EORTC) has sponsored a ran-
domized, multicenter, Phase III trial (NCT
00003152) to compare the effectiveness of combina-
tion chemotherapy followed by IFN alone versus
combination chemotherapy plus radiation and auto-
logous PBSCT 6 IFN-a maintenance for treating
adult (18-65 years) patients with de novo stage III or
IV FL. A total accrual of 469 patients is projected.PFS, OS, and toxicity are the primary outcome
measures.Radioimmunotherapy and Autologous SCT
Gisselbrecht et al. [38] reported the outcomes of
77 adult (31-64 years) patients with relapsed or refrac-
tory low grade lymphoma (90%FL) enrolled in aPhase
II GELA study investigating the efficacy of 90ttrium
ibritumomab tiuxetan (Zevalin) 1 BEAM (Z-BEAM)
followed by autologous SCT as a salvage regimen.
Most patients (96%) had received rituximab as part
of their salvage regimen. After a minimum follow-up
of 1 year for all patients, the estimated 2-year EFS is
93%. No toxic deaths were observed.Reduced-intensity conditioning (RIC) regimens
Autologous SCT versus RIC allogeneic SCT
Robinson et al. [39] compared the outcomes of
1504 adult (20-73 years) patients who underwent
464 Biol Blood Marrow Transplant 16:443-468, 2010D. M. Oliansky et al.either an autologous (n 5 1394) or RIC HLA-
matched sibling or HLA-matched unrelated donor
allogeneic (n 5 110) SCT between 1998 and 2005
and were reported to the EBMTR. At a median
follow-up of 26 months post-SCT, the 3-year PFS
was 62% versus 58% (P not stated) for patients who
underwent RIC allogeneic SCT versus autologous
SCT, respectively.
Laport et al. [40] reported the outcomes of 30 adult
(36-66 years) patients with relapsed FL enrolled in the
CTN0202 multicenter trial, comparing the efficacy
and toxicity of autologous SCT (n5 22) versus RIC al-
logeneic SCT (n 5 8). Patients were assigned to treat-
ment based on the availability of an HLA-matched
related donor. This trial closed early because of slow ac-
crual. At a median follow-up of 16 months, RIC alloge-
neic SCTpatients had superior 2-year PFS compared to
the autologousSCTpatients (100%versus 69%, respec-
tively, P5 .04). OSwas 100% versus 80% (P not stated)
for RIC allogeneic versus autologous SCT, and nonre-
lapse mortality was 0% and 15%, respectively (P not
stated).MA versus RIC allogeneic SCT
Sureda et al. [41] compared the outcomes of 144
patients with FL treated between 1991 and 2005
with RIC (n 5 93) versus myeloablative conditioning
(n 5 41) followed by an HLA-matched unrelated do-
nor allogeneic SCT and reported to the EBMT regis-
try. Forty-seven percent of patients had previously
undergone a failed autologous SCT. RIC patients
had significantly longer 3-year PFS (43% versus
35%, P 5 .004) and OS (49% versus 40%, P 5 .001)
than those treated with MA conditioning prior to allo-
geneic SCT. The 3-year nonrelapse mortality was
34% and 46% (P\ .001) for the RIC and MA condi-
tioning groups, respectively.
RIC allogeneic SCT
Corradini et al. [42] reported the outcomes of 194
patients with relapsed or refractory lymphomas (35%
low-grade NHL) enrolled in a prospective, multicen-
ter, Phase II study of the long-term outcomes of RIC
consisting of Cy 1 thiotepa 1 fludarabine followed
by allogeneic SCT from sibling donors. Median
follow-up was 5 years. The 5-year OS and PFS were
62% and 70% for low-grade NHL.
Khouri et al. [43] reported the long-term outcomes
of 47 adult (33-68 years) patients with recurrent chemo-
sensitive FL enrolled in a prospective, single-center,
Phase II study of RIC with Flu 1 Cy 1 rituximab fol-
lowedby anHLA-matched related (n5 45) or unrelated
(n5 2) donor allogeneic SCT.At amedian follow-up of
56 months, the 6-years OS and PFS rates were 85%
(95% confidence interval [CI], 71%-93%) and 83%
(95% CI, 69%-91%), respectively.STRENGTHS/LIMITATIONS AND
DISCUSSION
The strengths of this systematic evidence-based re-
view are the details conveyed in the text about each
study’s design, the presentation of outcomes in sum-
mary tables for each major section, and the treatment
recommendations made by the FL expert panel. A
limitation is the exclusion of nonpeer-reviewed data.
Unpublished data can represent ‘‘negative’’ findings
that could lead to publication bias; however, the inclu-
sion of high-quality, peer-reviewed publicly available
data was of paramount importance. Data published
in abstract form were not included because of the inad-
equate details of study design or patient characteristics,
making a true assessment of the widespread applicabil-
ity or impact of the treatment outside the scope of the
trial difficult.
A limitation of the FL literature is that there is
no consistency in the survival estimate time points,
making it difficult to compare outcomes across
studies. FL is an indolent disease requiring long
follow-up intervals; however, longer follow-up leads
to delayed publication, making it problematic to re-
flect up-to-date information. Although many studies
in this review reported short (\5 years) follow-up
intervals, much of the evidence presented in this re-
view does not reflect current clinical practice. For
example, most of the reviewed studies were con-
ducted prior to the U.S. FDA approval of rituximab;
therefore, the assumption of a benefit of rituximab
pre-SCT for FL has been extrapolated from evi-
dence of its use in aggressive NHL. The lengthy
process of conducting and reporting clinical research
emphasizes the need to identify surrogate molecular
markers that are predictive of long-term survival in
FL patients. In addition, further delineation of clin-
ical risk factors may facilitate appropriate selection
of follicular lymphoma patients for autologous ver-
sus allogeneic SCT.
A related limitation is that a number of FL studies
revealed plateaus on the Kaplan-Meier survival
curves, but did not always report how patients were
followed-up (passively or actively) or for how long.
Retrospective analyses of registry data are good for
obtaining long-term follow-up, but patients are het-
erogeneously treated, whereas randomized controlled
trials homogeneously treat patients, but usually pres-
ent data with shorter follow-up. This differential
follow-up could lead to under-reporting of MDS/
AML incidence, relapse rate, and late mortality.REFERENCES CITED IN ONLINE APPENDIX
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